ScholarLens Back to search
2014•Unpublished venueRequires access

FDA Approves Apremilast for Plaque Psoriasis

Lois Wingerson

Open publisher page 0 citations

Abstract

The FDA has approved the PDE4 inhibitor apremilast (Otezla) for plaque psoriasis. It was already approved for psoriatic arthritis.

About this research paper

What this paper is about

The FDA has approved the PDE4 inhibitor apremilast (Otezla) for plaque psoriasis. It was already approved for psoriatic arthritis.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The FDA has approved the PDE4 inhibitor apremilast (Otezla) for plaque psoriasis. It was already approved for psoriatic arthritis.

Key concepts: Apremilast, Plaque psoriasis, Medicine, Dermatology, Psoriasis, Business, Psoriatic arthritis

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
FDA Approves Apremilast for Plaque Psoriasis — Research Paper | ScholarLens